Compare VMD & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VMD | CBIO |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 537.5M |
| IPO Year | 2018 | 2013 |
| Metric | VMD | CBIO |
|---|---|---|
| Price | $9.10 | $20.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | ★ 413.2K | 202.1K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $270,280,000.00 | $18,500.00 |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $14.98 | $279.20 |
| P/E Ratio | $69.15 | ★ N/A |
| Revenue Growth | ★ 20.52 | N/A |
| 52 Week Low | $6.05 | $8.72 |
| 52 Week High | $12.61 | $27.41 |
| Indicator | VMD | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.89 | 68.70 |
| Support Level | $8.49 | $16.77 |
| Resistance Level | $10.05 | $21.14 |
| Average True Range (ATR) | 0.28 | 1.32 |
| MACD | 0.07 | 0.32 |
| Stochastic Oscillator | 54.55 | 80.79 |
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.